Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2012:4:413-21.
doi: 10.2147/IJWH.S13840. Epub 2012 Aug 17.

Tranexamic acid for the treatment of heavy menstrual bleeding: efficacy and safety

Henri Leminen  1 , Ritva Hurskainen
Affiliations

Tranexamic acid for the treatment of heavy menstrual bleeding: efficacy and safety

Henri Leminen et al. Int J Womens Health. 2012.

Abstract

Tranexamic acid has proven to be an effective treatment for heavy menstrual bleeding (HMB). It reduces menstrual blood loss (MBL) by 26%-60% and is significantly more effective than placebo, nonsteroidal anti-inflammatory drugs, oral cyclical luteal phase progestins, or oral etamsylate, while the levonorgestrel-releasing intrauterine system reduces MBL more than tranexamic acid. Other treatments used for HMB are oral contraceptives, danazol, and surgical interventions (endometrial ablation and hysterectomy). Medical therapy is usually considered a first-line treatment for idiopathic HMB. Tranexamic acid significantly improves the quality of life of women treated for HMB. The recommended oral dosage is 3.9-4 g/day for 4-5 days starting from the first day of the menstrual cycle. Adverse effects are few and mainly mild. No evidence exists of an increase in the incidence of thrombotic events associated with its use. An active thromboembolic disease is a contraindication. In the US, a history of thrombosis or thromboembolism, or an intrinsic risk for thrombosis or thromboembolism are considered contraindications as well. This review focuses on the efficacy and safety of tranexamic acid in the treatment of idiopathic HMB. We searched for medical literature published in English on tranexamic acid from Ovid Medline, PubMed, and Cinahl. Additional references were identified from the reference lists of articles. Ovid Medline, PubMed, and Cinahl search terms were "tranexamic acid" and "menorrhagia" or "heavy menstrual bleeding." Searches were last updated on March 25, 2012. Studies with women receiving tranexamic acid for HMB were included; randomized controlled studies with a description of appropriate statistical methodology were preferred. Relevant data on the physiology of menstruation and the pharmacodynamics and pharmacokinetics of tranexamic acid are also included.

Keywords: heavy menstrual bleeding; menorrhagia; tranexamic acid.

PubMed Disclaimer

Comment in

References

    1. Liu Z, Doan QV, Blumenthal P, Dubois RW. A systematic review evaluating health-related quality of life, work impairment, and healthcare costs and utilization in abnormal uterine bleeding. Value Health. 2007;10(3):183–194. - PubMed
    1. Rees M. Menorrhagia. Br Med J (Clin Res Ed) 1987;294(6574):759–762. - PMC - PubMed
    1. Hallberg L, Högdahl AM, Nilsson L, Rybo G. Menstrual blood loss–a population study. Variation at different ages and attempts to define normality. Acta Obstet Gynecol Scand. 1966;45(3):320–351. - PubMed
    1. Wyatt KM, Dimmock PW, Walker TJ, O’Brien PM. Determination of total menstrual blood loss. Fertil Steril. 2001;76(1):125–131. - PubMed
    1. US Food and Drug Administration. Drugs@FDA: Lysteda (tranexamic acid) label information. [Accessed March 19, 2012]. http://www.fda.gov [homepage on the Internet] Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/022430s002lbl.pdf.